ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivo

Executive Leadership UpdateArmata also announced the promotion of David House to Chief Financial Off

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports exp

Supports Phase 3 readiness of AP-SA02Non-dilutive DoD funding totals $28.7M to dateLOS ANGELES, June

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.16) per share which missed the a

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinica

The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion s

U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.43) per share which missed the a

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinica

HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) wit

Jones Trading analyst Debanjana Chatterjee initiates coverage on Armata Pharmaceuticals (AMEX:ARM

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.74) per share which missed the a

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a cl

Data highlights:The Phase 2a study enrolled and dosed 42 patients, with 29 randomized to AP-SA02 in

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-sta

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-sta

https://www.sec.gov/Archives/edgar/data/921114/000110465925077648/tm2523066d1_s3.htm

Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average vo

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.